tiprankstipranks
Prelude Therapeutics (PRLD)
NASDAQ:PRLD
US Market

Prelude Therapeutics (PRLD) Financial Statements

104 Followers

Prelude Therapeutics Financial Overview

Prelude Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.01; its P/E ratio is -2.27; Prelude Therapeutics is scheduled to report earnings on November 12, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -34.34M$ -37.38M$ -30.43M$ -27.72M$ -28.64M
EBITDA$ -33.92M$ -37.05M$ -29.80M$ -27.45M$ -28.02M
Net Income Common Stockholders$ -31.43M$ -33.08M$ -30.43M$ -27.72M$ -28.64M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 201.92M$ 232.94M$ 254.99M$ 172.25M$ 201.73M
Total Assets$ 247.11M$ 277.67M$ 280.61M$ 198.32M$ 220.50M
Total Debt$ 17.64M$ 16.89M$ 938.00K$ 1.39M$ 1.83M
Net Debt$ -184.28M$ -216.05M$ -254.05M$ -170.87M$ -199.90M
Total Liabilities$ 36.37M$ 40.58M$ 18.55M$ 23.02M$ 25.06M
Stockholders Equity$ 210.73M$ 237.09M$ 262.06M$ 175.30M$ 195.44M
Cash Flow-
Free Cash Flow$ -32.08M$ -24.71M$ -59.59M$ -30.94M$ -23.32M
Operating Cash Flow$ -31.79M$ -23.58M$ -57.80M$ -30.13M$ -22.93M
Investing Cash Flow$ 31.22M$ 7.74M$ -57.43M$ 18.00M$ 1.35M
Financing Cash Flow$ -14.00K$ 25.24M$ 111.07M$ -269.00K$ 155.00K
Currency in USD

Prelude Therapeutics Earnings and Revenue History

Prelude Therapeutics Debt to Assets

Prelude Therapeutics Cash Flow

Prelude Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis